Biogen agreed to acquire TJ Biopharma’s exclusive rights to felzartamab in Greater China, giving Biogen exclusive worldwide rights to the drug candidate. The deal strengthens Biogen’s pipeline and expands its control over a potentially important biotech asset. The article is truncated, so no transaction value or clinical details are provided.
Biogen agreed to acquire TJ Biopharma’s exclusive rights to felzartamab in Greater China, giving Biogen exclusive worldwide rights to the drug candidate. The deal strengthens Biogen’s pipeline and expands its control over a potentially important biotech asset. The article is truncated, so no transaction value or clinical details are provided.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.45
Ticker Sentiment
